Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
Glaukos announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a first-in-class tri-specific biologic targeting VEGF-A, VEGF-C, and Ang-2 for retinal diseases including nAMD, DME, DR, and RVO. The deal also grants Glaukos exclusive rights to RevOpsis' RevMod platform to discover up to four additional next-generation retinal biologic candidates.
Key figures
- Drug Name
- RO-104
- Phase Of Trial
- preclinical
- Additional candidates licensed
- 4
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.